Stay updated with breaking news from Pathol Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023
Approval based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca's ENHERTU reduced the risk of disease progression or death by 50% and increased median overall survival by more than
Investegate announcements from AstraZeneca PLC, Enhertu recommended for EU approval in HER2-low BC
DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of Daiichi Sankyo and A
Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan demonstrated superior progression-free and overall survival versus chemotherapy Daiichi